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A B S T R A C T
The nitrone spin trap 5,5‑dimethyl‑1‑pyrroline N‑oxide (DMPO) dampens endotoxin-induced and TLR4-driven
priming of macrophages, but the mechanism remains unknown. The available information suggests a direct bind-
ing of DMPO to the TIR domain, which is shared between TLRs. However, TLR2-TIR domain is the only TLR that
have been crystallized. Our in silico data show that DMPO binds to four specific residues in the BB-loop within
the TLR2-TIR domain. Our functional analysis using hTLR2.6-expressing HEKs cells showed that DMPO can block
zymosan-triggered-TLR2-mediated NF-kb activation. However, DMPO did not affect the overall TLR2-MyD88
protein-protein interaction. DMPO binds to the BB-loop in the TIR-domain and dampens downstream signaling
without affecting the overall TIR-MyD88 interaction. These data encourage the use of DMPO-derivatives as po-
tential mechanism-based inhibitors of TLR-triggered inflammation.
1. Introduction
Spin traps are low-molecular-weight compounds that covalently
bind to radical sites in radicalized molecules, and thus can stop free
radical chain reactions that otherwise end in end-oxidation products
[1]. Nitrone spin traps such as N‑tert‑butyl‑α‑phenylnitrone (PBN) and
5,5‑dimethyl‑1‑pyrroline N‑oxide (DMPO) were originally developed
with the purpose of trapping and stabilizing free radicals, thus making
possible their study by electron spin resonance or immuno-spin trap-
ping [2,3]. However, these nitrones have been proved to have anti-in-
flammatory properties on several experimental models [4]. Both spin
traps are able to dampen lipopolysaccharide (LPS)-triggered signal-
ing related to mitogen-activated protein kinase, protein kinase B, in-
ducible nitric oxide synthase, cyclooxygenase-2 and pro-inflammatory
cytokines [5,6] suggesting that these effects may be related to their ni
trone motif. These anti-inflammatory effects are unlikely to be related
to their free radical trapping properties because of the low reaction rate
constant of this reaction [7].
Currently, DMPO or any of its structural analogs, have not been
moved into the drug development pipeline. That may be due to DMPO
synthesis being really expensive in comparison to PBN and its deriv-
atives. PBN-analogs have been synthesized and their anti-inflamma-
tory properties have been tested in different experimental models [4,8].
Moreover, some of them have reached phase III clinical trials, but the
mechanisms behind these effects remain obscure [4].
By using DMPO as a tool we have studied the intracellular local-
ization and identity of radicalized protein in cells, tissues and whole
animals [9,10]. Interestingly, DMPO dampened LPS-driven
RAW264.7-macrophage-like cell line activation, thus prevented nitric
oxide and inflammatory chemokine production. These effects afforded
by DMPO were linked to inhibition of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-ĸB) signaling path-
way at early time points after
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the stimulus (i.e., 15min) [5]. We have also studied the effects of DMPO
on the transcriptome of macrophages and found that the spin trap was
able to change the expression of 215 genes when added simultaneously
with LPS on RAW 264.7 cells for 6h. Interestingly, 75% of those genes
were downregulated when compared to LPS stimulated cells. Functional
analysis of these genes using Ingenuity Pathway Analysis (IPA) soft-
ware was consistent with a negative regulation of the innate immune
system with several toll-like receptors (TLR-4, -3 and -9) indicated as
receptors being affected by DMPO [11] (Fig. 1). Currently, the exact
mechanism by which spin traps exert their anti-inflammatory effects re-
mains unknown. However, the production of mechanism-based drugs is
an emerging field that will lead to safer anti-inflammatory drugs. This
can be moved forward by knowing the exact changes in transcriptome,
proteome, and phenome induced by DMPO in inflammatory cells, such
as macrophages. In this regard, transcriptomic and functional changes
induced by DMPO in macrophages, as we have recently reported [11],
may be an important step towards accomplishing this goal.
Toll-like receptors sense conserved pathogen- and danger-associated
molecular patterns released by microbes and the host [12]. Among the
most studied TLRs, TLR4 is well known because of its participation in
inflammatory response triggered by LPS. Closely related, TLR2 binds
peptidoglycan and it is necessary for the correct signaling triggered by
LPS throughout TLR4 [13,14]. Interestingly, all TLRs have in common
a cytoplasmic domain called toll-interleukin-1 receptor (TIR) that me-
diates interactions with adaptor molecules such as myeloid differentia-
tion primary response 88 (MyD88) and Toll-interleukin 1 receptor do-
main containing adaptor protein (TIRAP) [15]. A region called BB-loop
within the TIR domain has been pointed as a critical region for a suc-
cessful TLR downstream signal transduction. Indeed, a site-directed mu-
tation of one residue at the BB-loop (called after the β-sheet and α-
Fig. 1. TLR4 predicted as inhibition by IPA software analysis on the transcriptome of
LPS-primed RAW 264.7 cells in the presence of DMPO. Figure displays how molecules pre-
dicted (blue) are related to each other and the behavior of genes downstream of these in-
teractions. Solid lines correspond to direct physical interactions. Dashed lines correspond
to indirect interactions. CCL2, CCL7, IRF7, and CD40 are highlighted in green indicat-
ing down-regulation of its mRNAs expression in the DMPO+LPS vs LPS comparison. It is
important to highlight that most of the upstream regulators are predicted as inhibitions,
which is consistent with DMPO dampening the entire signaling related to LPS-triggered
TLRs signaling. Extracted from Muñoz et al. [11].
helix motifs that compose the tridimensional structure) region (P712 in
murine TLR4 and its analog on human TLR2-P681) results in signal im-
pairment [16,17]. This evidence points the BB-loop within the TLR's TIR
domain as a rational target for attenuation of TLRs signaling. To the
date, TLR4-TIR domain has not yet been crystallized making impossi-
ble to perform in silico studies on this receptor's domain. On the other
hand, TLR2-TIR domain has already been crystallized and has many
structural and functional similarities with TLR4 [13,14] making it a suit-
able experimental model for docking and molecular dynamics studies
on TLR-TIR signaling.
These pieces of evidence led us to hypothesize that the anti-inflam-
matory effects of DMPO can be explained by direct binding of the spin
trap to the TIR domain of TLRs. To test this hypothesis we combined
in silico techniques of docking, molecular dynamics simulations and
QTAIM (Quantum Theory of Atoms In Molecules) calculations to deter-
mine the site and strength of the interaction between DMPO and TLR2
TIR domain, as well as biochemical techniques to determine the func-
tional significance of our findings.
2. Materials and methods
2.1. Blind docking setup
The three-dimensional crystal structure of TLR2 TIR domain em-
ployed in this work was obtained from the Protein Data Bank ID code
1FYW. This structure was subjected to energy minimization calculations
to remove possible bumps using the Amber16 package.
The docking simulations were carried out using of AutoDock 4.2
[18]. The docking of the DMPO was performed on the entire TLR2 TIR
domain surface without prior specification of the binding site (“blind
docking”). In docking experiments the following parameters were used:
the initial population of trial ligands was composed of 250 individu-
als; the maximum number of generations was set to 270,000. The max-
imum number of energy evaluations was 10.0×10⁠6. All other parame-
ters were maintained at their default setting. The 3D affinity map was
a cube with 126×126×126 points separated by 0.375Å and centered
at the TLR2-TIR domain. The resulting docked conformations were clus-
tered into families by the backbone rmsd. The lowest docking-energy
conformation for each family was considered as the most favorable ori-
entation.
2.2. Refinement of the anchoring/binding mode
After the docking calculations, leading lowest energy structures were
refined by performing molecular dynamics simulations, using the Am-
ber16 packet. The molecular dynamics simulations (MD) were per-
formed using the all-atom force field ff99SB [19] to describe the re-
ceptor, whereas the general Amber force field (GAFF) [20] was used to
handle small organic molecules and the force field parameters of the
inhibitors were produced by the antechamber program in Amber. The
water molecules were represented by the TIP3P model. Each model was
soaked in a truncated octahedral-periodic box of TIP3P water molecules.
The distance between the edges of the water box and the closest atom of
the solutes was at least 10Å. Sodium ions were added to neutralize the
charge of the system. The entire system was subjected to energy mini-
mization.
Next, each system was heated in the NVT ensemble from 100 to
300K in 500ps and equilibrated at an isothermal-isobaric (NPT) en-
semble for another 500ps. A Langevin thermostat [21] was used for
temperature coupling with a collision frequency of 1.0ps⁠−1. The Parti-
cle Mesh Ewald (PME) method was employed to treat the long-range
electrostatic interactions in a periodic boundary condition [22]. The
SHAKE method was used to constrain hydrogen atoms. The time step
for all MD is 2 fs, with a direct-space, non-bonded cut-off of 8Å. Fi
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nally, the production was performed at the NPT ensemble by running
three independent simulations with length limited to 20ns, accounting
for a total simulation length of 60ns. The only difference between repli-
cates was the initial velocity assignments at the beginning of the dynam-
ics.
2.3. The MM-PBSA method
In MM-PBSA [23], the binding free energy (ΔGbind) resulting from
the formation of an RL complex between a ligand (L) and a receptor (R)
is calculated as:
where ΔEMM, ΔGsol, and -TΔS are the changes of the gas phase MM
energy, the solvation free energy, and the conformational entropy upon
binding, respectively. ΔEMM includes ΔEinternal (bond, angle, and di-
hedral energies), ΔEelectrostatic (electrostatic), and ΔEvdw (van der
Waals) energies. ΔGsolv is the sum of electrostatic solvation energy (po-
lar contribution), ΔGGB, and the non-electrostatic solvation component
(nonpolar contribution), ΔGSA. The polar contribution is calculated us-
ing the GB model, while the nonpolar energy is estimated by solvent ac-
cessible surface area (SASA). The conformational entropy change, -TΔS,
is usually computed by normal-mode analysis, but in this study, the en-
tropy contributions were not calculated due to the computational cost
involved in such calculations.
2.4. QM/MM setup
A two-layer ONIOM (QM/MM) method has been used [24]. The
compound DMPO and the side chains of the residues that have at least
one heavy atom within 5 A ̊ from the ligand molecule was incorporated
into the high-level QM layer and the remainder of the complex system
was included in the low-level MM layer. The QM region was calculated
using the M062X/6-31G(d) method [25] and the MM portion using the
AMBER force field [20,26]. The MM parameters absent in the standard
AMBER force field were included from the generalized AMBER force
field [20]. Only the geometry of the QM layer was fully optimized.
2.5. Atoms in molecules theory
From the Quantum Theory Atoms In Molecules (QTAIM) point of
view, two interacting atoms share three topological elements related to
each other, a point, a line, and a surface. The first element is the bond
critical point (BCP), namely the critical point in ρ(r) topology that is
found between any two interacting nuclei. From each BCP, two unique
trajectories of gradient vectors of electronic density, ∇ρ(r), originate at
that point and terminate at each of the neighboring nuclei. These tra-
jectories define a line along in which ρ(r) is a maximum with respect
to any neighboring line. This line that constitutes the second element
is the bond path (BP). Additionally, the set of trajectories that termi-
nate at a BCP define the interatomic surface that separates the atomic
basins of the neighboring atoms. The topological properties of a scalar
field such as ρ(r) are summarized in terms of their critical points (i.e.,
the points rc where Δρ(r)=0). Critical points are classified according
to their type (ω, σ) by stating their rank (ω), and signature (σ). Critical
points of (3, −1) and (3, +1) type describe saddle points, while the (3,
−3) is a maximum and (3, +3) is a minimum in the field. Among these
critical points, the (3, −1) or bond critical point was used to describe
ligand-receptor interactions. The wave functions of the inhibitor com-
plexed to the binding site residues (residues that have at least one
heavy atom within 5Å from the DMPO molecule) were generated at
the M062X/6-31G(d) level of theory. Such systems were subjected to a
QTAIM analysis [27] using Multiwfn software [28]. This type of calcu-
lations has been used in recent works because it ensures a reasonable
compromise between the wave function of enough quality to obtain reli-
able values of the derivatives of ρ(r) and the computer power available,
due to the extension of the analyzed systems [29–31].
2.6. Gene-reporter assay for NF-κB activity in hTLR2.6 expressing HEK293
cells
HEK293 cells transfected with human TLR2.6 (hTLR2.6) were ob-
tained from Invivogen and grown in DMEM (GIBCO, Cat#11995073)
supplemented with 10% fetal calf serum (FCS, Biowest, Cat# S1810)
and 10μg/ml blasticidin S (Invivogen Cat#A1113903). The day of the
experiment cells (3.10 ⁠4 cells/100μl) were seeded in 96-well plates for
24h before transfection. The cells were transiently transfected with
the NF-κB-driven secreted alkaline phosphatase (SEAP) reporter con-
struct (pNiFty-SEAP, Invivogen, Cat# 17C17-MM) using Lipofectamine
2000™ (Invitrogen, Cat#11668–019). After a 24h-exposure to the
transfection mixture, the cells were stimulated for 24h with 66.7μg/
ml zymosan (Sigma, Cat#58856-93-2) and/or 50mM DMPO (Dojindo,
Cat#D048-10). SEAP activity in the cell supernatants was measured
by a colorimetric assay using the QUANTI-Blue™ substrate (Invivogen,
Cat#18A22-MM). QUANTI-Blue™ medium changes to a purple-blue
color in the presence of SEAP. Optical densities were measured by a mi-
croplate reader (GENios, TECAN) at 620nm. All experiments were inde-
pendently repeated at least 3 times with triplicates within each plate.
2.7. MyD88-TLR2 co-immunoprecipitation
THP-1 cells (American Type Culture Collection, Cat#TIB-202™)
were cultured in RPMI 1640 medium (Gibco, Cat#R0883) modified to
contain 2mMl-glutamine, 4500mg/L glucose, and 1500mg/L sodium
bicarbonate, and were supplemented with 10% (vol/vol) heat-inacti-
vated FCS. THP-1 cells were plated at 5×10⁠6 cells per well in T-25ml
tissue bottles with 50ng/mL phorbol 12-myristate 13-acetate (PMA,
Sigma, Cat#P1585-1MG) for 24h. Adherent cells were rinsed with
phosphate-buffered saline (PBS) and then treated with 100μg/ml zy-
mosan (Sigma, Cat#58856-93-2) in the presence or in the absence
of 50mM DMPO for 15min. After incubation, cells were rinsed with
ice-cold PBS and whole-cell proteins were extracted using Mild Ly-
sis Buffer containing 50mM TRIS (pH7.4), 150mM NaCl, 20mM NaF,
1% Igepal, 1mM Na⁠3VO⁠4 and protease inhibitor (Roche Applied Sci-
ence, Cat#11 836 153 001). Proteins extracted were quantified us-
ing BCA Protein Assay Reagents (Thermo Scientific/Pierce, Cat#23225)
and incubated with the anti-TLR2 antibody (Santa Cruz Technologies,
Cat#sc-21760) overnight at 4 °C with rotation. Prewashed 50 ul pro-
tein G-agarose (Roche, Cat#11 243 233 00) was added to each sample
and rotated at 4 °C for 4h. Beads were then washed three times in lysis
buffer (without protease inhibitor) and finally in complete lysis buffer.
Beads were resuspended in 4× Laemmli sample buffer and boiled for
10min. Immunoprecipitated proteins were separated by 4–12% SDS/
PAGE, transferred onto a nitrocellulose membrane, blocked, and incu-
bated with the anti-TLR2 antibody, and anti-Myd88 antibody (Santa
Cruz Technologies, Cat#sc-11356) for 1h. Development was carried
out using HRP-linked secondary antibody (Santa Cruz Technologies,
Cat#sc-516102) and bands were visualized using ECL Plus Reagents
(Amersham Pharmacia Biotech, Cat#RPN2132) in a myECL imager
(ThermoScientific/Pierce). Band intensity was analyzed using ImageJ
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software [32]. Results are shown as TLR2-My88 ratio of 3 independent
experiments.
3. Results
3.1. Identification of DMPO binding sites and energy interaction within the
TLR2-TIR domain
Because several TLRs share a region called BB-loop which is respon-
sible for signal transduction [16] we hypothesize that the effects of
DMPO could be explained by direct binding to BB-loop region within
TLRs. Because TLR2 TIR domain is the only one crystallized, we per-
formed a preliminary blind docking analysis using the Lamarckian ge-
netic algorithm [18] on this domain. The solutions were sorted in terms
of ΔGbind, and the lowest docking energy conformations of each clus-
ter were considered to be the most stable orientations. Fortunately,
the surface of TIR is not very extensive (only 149 residues long) and
therefore only six different putative sites where DMPO can bind were
found (Fig. 2). Fig. 2A shows the topology of site 2 and specific residues
located in there, whereas Fig. 2B, shows the topology of sites 1, 3 and
6; and Fig. 2C shows the topology of sites 4 and 5.
In a second stage, six molecular dynamic simulations were per-
formed, starting from the coordinates of each representative of the best
ranked TIR-DMPO complexes (C1–C6), which were obtained from the
blind docking experiment. The complexes were subjected to 20.0ns MD
simulation and results are shown in Table 1.
Furthermore, we calculated the relative binding free energies
(ΔΔGbind) of the 6 complexes listed above in order to identify the struc-
tural thermodynamic characteristics of the binding site into the TIR do-
main. Results are shown in Table 2. It should be noted that the inade-
quacies of the models, the implicit limitations of the method, and the
simplifications in its applications should be canceled when the relative
free energies (ΔΔGbind) rather than absolute (ΔGbind) energies are cal-
culated [33].
Considering the results displayed in Table 2, complex 2 emerges as
the best ranked from the six analyzed complexes. Noteworthy, site 2 is
Fig. 2. Topographic location of the six DMPO-binding sites at the TLR2-TIR domain as found from the blind docking procedure. The TIR domain is shown in white color; whereas the
spatial location of the preferred six DMPO-binding sites is shown in green. A) Site 2 and residues involved in DMPO binding. B) Sites 1, 3 and 6; C) Sites 4 and 5. Amino acids included in
each binding site are listed in Table 1.
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Table 1
Summary of results obtained from blind docking analysis. Free energy of the TIR-DMPO
complexes are shown here.
Potential binding
pocket (Site)
Member
in cluster
Lowest
energy
Residues located at <5Å from the
best-docked conformation
1 131 −4.54 I693, H697, K698, T699, F3722,
N729, D730, A731, I733
2 41 −4.09 Y641, D678, I680, K683, D687,
N688, D691, S692, K695
3 104 −4.01 A732, I733, L734, I735, T760, Y761,
L762
4 17 −3.84 L736, L737, E738, P739, L762,
E763, W764, P765
5 3 −3.75 Y761, L762, E763, P765, Q770,
G763, F774, N777
6 4 −3.38 R675, F679, I680, K683, W684,
I685, I686, D687, N688
located in the BB-loop adjacent to the conserved residues P681 and
G682. This result was highly encouraging because the identified bind-
ing site where DMPO fits the TIR domain has previously been found
to be important in downstream signaling [17]. To investigate which
residues within the binding site, identified as located in complex 2, are
responsible for the binding affinities for DMPO, an energy decompo-
sition analysis was performed. Fig. 3 shows the results of plotting the
ΔGtot contribution versus each TIR residue. The binding between TIR
and DMPO located at binding site 2 is driven by selected “hot spots”
that play a major role in TIR-DMPO recognition. The most important
residues are D678, F679, I680, K883, and K695 which were found to be
involved in several non-covalent interactions with DMPO. It should be
noted that the molecular interaction with K683 is the strongest one, and
therefore it appears that such interaction might be one of the anchor-
ing points which stabilize the complex. In addition, other interactions
somewhat weaker with Y641, S682, D687, and N688 complete the in-
teractions to stabilize the complex.
3.2. Evaluation of the molecular interactions (MI) of the TIR-DMPO
complex using QTAIM calculations
The topological analysis of the electron density constitutes a pow-
erful tool to investigate the electronic properties of a molecular sys-
tem and allows a deep examination of the molecular interactions. We
have demonstrated that utilizing QTAIM calculations, it is possible to
determine in an unequivocal way, the different interactions (strong and
weak ones) between two atoms throughout the existence of bond criti-
cal points (BCPs) and their respective bond paths. Thus, the intermole-
cular interactions of the complex TIR-DMPO were evaluated using the
QTAIM technique. Results are summarized in Fig. 4. These are the sum
of the charge density values at the intermolecular BCPs between DMPO
Table 2
Free energy results of the best ranked TIR-DMPO complexes (C).
Component C1 C2 C3 C4 C5 C6
Mean⁠a Std⁠b Mean Std Mean Std Mean Std Mean Std Mean Std
ΔE⁠vdW −17.46 1.30 −19.40 1.03 −16.19 1.07 −17.30 1.17 −14.20 0.96 −14.56 0.82
ΔE⁠ele −5.63 0.59 −5.83 0.57 −1.68 0.45 0.41 0.42 −1.32 0.32 −0.38 0.38
ΔG⁠PB 9.89 0.53 11.74 0.60 4.45 0.35 5.43 0.49 4.25 0.27 5.70 0.44
ΔG⁠SASA −1.94 0.02 −1.85 0.02 −1.57 0.03 −1.72 0.02 −1.49 0.02 −1.63 0.02
ΔE⁠gas −23.09 1.21 −25.23 1.05 −17.87 1.07 −16.89 1.18 −15.51 1.05 −14.94 0.89
ΔG⁠solve 7.96 0.53 9.89 0.60 2.88 0.34 3.70 0.48 2.76 0.26 4.07 0.43
ΔG⁠Bind −15.13 1.26 −15.34 1.03 −14.99 1.04 −13.19 1.27 −12.75 0.96 −10.87 0.90
ΔΔG⁠Bind 0.21 0.00 0.35 2.16 2.59 4.47
a Average value.
b Standard deviation.
Fig. 3. Histogram of the interaction energies partitioned with respect to the TIR-DMPO complex 2. The x-axis denotes the residue number of TIR domain, and the y-axis denotes the
interaction energy between DMPO and specific amino acid residues within the potential binding pocket (site) 2 at the TIR domain. These amino acid residues composing site 2 are located
at the BB-loop region within the TLR2-TIR domain.
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Fig. 4. Overall interaction energy between specific amino acid residues at the TLR2-TIR-BB-loop region and DMPO. Sum of the values of charge density (∑ρ(r)) resulting from hydrogen
bonds and hydrophobic interactions established between specific amino acid residues at the BB-Loop region and DMPO. The BB-Loop is located at the potential binding site 2 within the
TLR2-TIR domain. Only the intermolecular interactions are added in the sum. a.u., arbitrary units.
and specific amino acid residues at the BB-loop region within of TIR
domain are shown. Fig. 4 also shows four anchor points: Y641, K683,
N688, and N691. It is important to note that K683 presents a strong hy-
drogen bond with DMPO, whereas the hydrogen bonds formed with the
other amino acid residues are moderate. Moreover, the residues F679,
I680, N688 establish several hydrophobic interactions with DMPO that
although they are individually weak, as a whole they significantly con-
tribute to the overall binding energy, and probably to the function of
such interaction.
To better appreciate the different MIs obtained in this complex,
the interactions were also displayed using two alternative illustrations.
Fig. 5a showing the main hydrophobic interactions observed for the
DMPO-TIR complex and Fig. 5b showing the most relevant polar inter-
actions obtained for the complex.
3.3. Inhibition of toll-like receptor 2 signaling by DMPO
Blind docking, molecular dynamics and QTAIM calculation descript
the most likely interaction between DMPO and the BB-loop region at
the TLR2-TIR domain responsible for downstream signal transduction.
In order to test whether our in silico simulations had a functional con-
sequence we assessed the effect of DMPO on TLR2 signaling using tran-
sient transfection of NF-κB reporter plasmid into HEK293 cells trans-
fected with human TLR2.6 and then we stimulated them with zymosan
in the presence or in the absence of DMPO. The results showed an
inhibitory effect of DMPO on zymosan-triggered TLR2 signaling when
added to culture medium (Fig. 6).
3.4. Effect of DMPO on TLR2-MyD88 coupling
It has been reported that inhibition of TLR2 signaling can be
achieved using small peptides targeting the BB-loop region of TIR caus-
ing disruption of TLR2-MyD88 interaction [17]. Based on this piece of
evidence and our in silico and in vitro data, we tested the effect of DMPO
on TLR2-MyD88 protein-protein interaction using the co-immunopre-
cipitation technique in macrophage-like cells derived from THP-1 cell
line. It is important to highlight the fact that THP-1 cells used in this
experiment have to be properly differentiated into macrophage-like
cells using phorbol 12-myristate 13-acetate (PMA),
Fig. 5. Non-covalent interactions between DMPO and specific residues within the
TLR2-TIR-BB-loop region. DMPO structure is shown as yellow sticks. A) hydrogen bond
interactions and B) hydrophobic interactions. The elements of the electron density topol-
ogy are shown. The bond paths connecting each nucleus are shown as pink sticks and the
bond critical points are shown as red spheres.
before TLR2 stimulation [34]. This previous step may affect the basal
level of TLR2-MyD88 coupling, thus affecting our results.
Results shown in Fig. 7 indicate that the presence of the spin trap
does not block zymosan-induced protein-protein interaction between
TLR2 and its adaptor protein MyD88.
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Fig. 6. Functional determination of the effect of DMPO on zymosan-triggered TLR2-me-
diated NF-κB activation. HEK293 hTLR2.6-expressing cells were transfected with the
NF-κB-reporter construct to test TLR2 signaling specifically. Then cells were treated with
TLR2 stimulus (100μg/ml zymosan) in the presence or in the absence of 50mM DMPO.
TLR-2-mediated NF-κB activation was measured as SEAP activity as described in the
Materials and Methods section. Culture medium was used as the control. All experiments
were independently repeated at least 3 times by triplicate in each experiment. Results are
shown as mean values±SEM. * P value<0.01. A.U., arbitrary units.
Fig. 7. Effect of DMPO on TLR2-MyD88 protein-protein interaction after zymosan trig-
gered TLR2 signaling in macrophages. Human macrophage-like cells were differentiated
from THP-1 cells by treatment with PMA. Then TLR2 signaling was triggered with 100μg/
ml zymosan in the presence or in the absence of 50mM DMPO for 15min. Co-immunopre-
cipitation was performed using anti-TLR2 antibody and anti-MyD88 antibody. A) The op-
tical density of immunoprecipitated proteins. Pulled-down proteins were analyzed as de-
scribed in the Materials and Methods section. Results are shown as mean values±SEM of
the TLR2-My88 ratios. * P value<0.05. B) Picture of the most representative western-blot
image.
4. Discussion
Herein we have determined and measured, for the first time, the in-
teraction between DMPO and four-specific residues within the BB-loop
region of TLR2 TIR domain, and its functional consequences in signal-
ing. To our knowledge, this is the first evidence showing the mecha-
nism of DMPO dampening TLR2 signaling that may be extended to other
TLRs, such as TLR4.
Mistry et al. have provided convincing data showing that targeting
the BB loop pocket is an effective approach for the identification of
TLR2 signaling inhibitors [35]. In our study, the combination of blind
docking and subsequent MD simulations indicated that site 2 is the
most likely to which DMPO would be bound in TLR2-TIR domain. This
site where DMPO fits into the TIR domain has been previously found to
be important in downstream signaling [17]. Particularly, residue P681
has a critical role in TLR2 triggered signaling as shown by site-directed
mutagenesis technique [17,35]. Moreover, a naturally occurring allele
of mouse TLR4 has been reported to be unresponsive to LPS due to a
point mutation on residue P712, a structural analog of human TLR2
P681 residue [16,17].
The evaluation of the molecular interactions of the TIR-DMPO com-
plex by using QTAIM calculations indicates that the complex shows four
main anchor points: Y641, K683, N688, and N691. Whereas K683 pre-
sents a strong hydrogen bond, the other hydrogen bonds are moder-
ate. On the other hand, the residues F679, I680, N688 presents several
hydrophobic interactions with DMPO that although they are individu-
ally weak, as a whole (making an additive effect) they contribute sig-
nificantly to the stability of the complex. From our results, a complete
structural description for this DMPO-binding site, including the different
interaction stabilizing the TIR-DMPO complex, has been obtained. The
full coordinates of this complex are available as supplementary material
(See Supplementary materials).
Protein-protein interactions between the TLR2-TIR-BB-Loop domain
with the BB-loop within MyD88 are important to ensure functional
downstream signaling. Thus, according to our in silico data, we tested
whether by non-covalently binding to those specific residues at the
BB-loop domain DMPO may reduce the effective downstream signaling.
To test this possibility we measured the functional effects of DMPO on
zymosan-triggered TLR2 signaling and found that DMPO inhibits down-
stream signaling. It is important to highlight that the HEK293 cells do
not express TLRs [36], hence our findings on TLR2 signaling are only
linked to this specific receptor. These results support ours in silico sim-
ulations where DMPO was found to directly bind to a key region re-
sponsible for signal transduction, i.e., the BB-loop within the TLR2-TIR
domain. DMPO interferes the signaling triggered by zymosan-induced
protein-protein interaction between TLR2-TIR-BB-loop with its adaptor
protein MyD88.
Because DMPO inhibits the function of the TLR2-TIR-BB-loop/My-
D88 protein-protein interaction, it may be because DMPO binds to a
critical site needed for this interaction. In other words, by binding to
one or more specific amino acid residues within the TLR2-TIR-BB-Loop
region DMPO may block the binding of TLR2-TIR with MyD88. Thus we
measured the effect of DMPO on the binding of TLR2 with MyD88 upon
zymosan activation in THP-1-derived macrophages. Our co-immunopre-
cipitation data suggest that DMPO does not inhibit TLR2-MyD88 pro-
tein-protein interaction. However, this observation does not necessarily
mean that DMPO binding to the BB-loop inhibits, in term of downstream
signaling, the functionality of the TLR2-MyD88 protein-protein interac-
tion. The spin trap could be disrupting the proper interaction of TLR2
with the adaptor protein without completely inhibiting the protein-pro-
tein interaction. These findings are consistent with our previously pub-
lished data and propose an explanation for the observed phenomenon
of multiple TLRs inhibition by DMPO, as we have previously reported
[11].
Our data and the fact that TIR-BB-loop region is conserved through-
out different TLRs and species empowers further studies of the effects of
DMPO on other TLRs and encourages the use of nitrone spin traps (or
their derivates) as mechanism-based anti-inflammatory drugs.
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